These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9484527)

  • 1. International Symposium on Somatostatin Analogs: Basic Update and Clinical Perspectives. Venice, Italy, October 24-25, 1997. Abstracts.
    J Endocrinol Invest; 1997; 20(7 Suppl):1-106. PubMed ID: 9484527
    [No Abstract]   [Full Text] [Related]  

  • 2. [International symposium on somatostatin analogues: fundamental aspects and clinical perspectives. Venice, Italy, 24-25 October 1997. Abstracts].
    Ann Endocrinol (Paris); 1998; 59 Suppl 2():1-52. PubMed ID: 10065269
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives of new potential therapeutic applications of somatostatin analogs.
    Pawlikowski M; Melen-Mucha G
    Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New developments in somatostatin analogs and their receptors].
    Jaquet P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S3-4. PubMed ID: 12037500
    [No Abstract]   [Full Text] [Related]  

  • 5. Somatostatin analogs in the treatment of acromegaly: the choice is now possible.
    Chanson P
    Eur J Endocrinol; 2000 Nov; 143(5):573-5. PubMed ID: 11078979
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of somatostatin analogs in the control of tumor growth.
    Lamberts SW; Reubi JC; Krenning EP
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):61-4. PubMed ID: 7992085
    [No Abstract]   [Full Text] [Related]  

  • 7. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action.
    Woltering EA; Watson JC; Alperin-Lea RC; Sharma C; Keenan E; Kurozawa D; Barrie R
    Invest New Drugs; 1997; 15(1):77-86. PubMed ID: 9195291
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for treating cancer with somatostatin analogs.
    Minuto F; Ferone D; Arvigo M; Barreca A
    J Endocrinol Invest; 2003; 26(8 Suppl):117-9. PubMed ID: 15233226
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of somatostatin analogs on biochemical parameters in acromegaly.
    Liuzzi A; Marzullo P
    J Endocrinol Invest; 2003; 26(8 Suppl):46-9. PubMed ID: 15233212
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.
    Burt MG; Ho KK
    Endocrine; 2003 Apr; 20(3):299-305. PubMed ID: 12721511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogs in medical treatment of acromegaly.
    Racine MS; Barkan AL
    Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtypes: targeting functional and therapeutic specificity.
    Culler MD; Taylor JE; Moreau JP
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S5-12. PubMed ID: 12037501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of somatostatin analogues in paediatric oncology.
    Albers AR; O'Dorisio MS
    Digestion; 1996; 57 Suppl 1():38-41. PubMed ID: 8813466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin and somatostatin receptors in Cushing's disease.
    Hofland LJ
    Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor physiology and targets for somatostatin analogue therapy. Abstracts of the Young Investigator Meeting. 31 October-2 November 2002, Barcelona, Spain.
    Eur J Endocrinol; 2003 Jan; 148 Suppl 1():50 pages. PubMed ID: 12602334
    [No Abstract]   [Full Text] [Related]  

  • 16. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 17. [Somatostatinergic control of Kaposi's sarcoma growth through the inhibition of angiogenesis].
    Corsaro A; Thellung S; Villa V; Arena S; Noonan D; Albini A; Schettini G; Florio T
    Minerva Endocrinol; 2001 Dec; 26(4):273-6. PubMed ID: 11782715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer.
    Stolz B; Smith-Jones P; Albert R; Tolcsvai L; Briner U; Ruser G; Mäcke H; Weckbecker G; Bruns C
    Digestion; 1996; 57 Suppl 1():17-21. PubMed ID: 8813461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pasireotide as a new second-line treatment option].
    Strathaus RS
    Med Monatsschr Pharm; 2015 May; 38(5):194-5. PubMed ID: 26364410
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
    Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P
    J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.